Pulmonx's First Growth Quarter Is a Junior-Rep Story
The headline is real; the base is low
Pulmonx reported $22.8 million of third-quarter revenue, up 6% year over year, and management led with the milestone: “marking our organization's return to revenue growth with a 6% increase over the prior year period.” — Glendon E. French · 2026-10-27 U.S. revenue rose 7% to $14.9 million; international rose 5% to $7.9 million, or about 9% excluding China. The company added 8 new U.S. treating centers—down from 12 in Q2 and 15 in Q1, though still ahead of its 40-a-year pace year-to-date. The return to growth is the first since CEO Glenn French and CFO Derrick Sung rejoined the company, and the stock has noticed: shares are up 56% over the last 90 days, even after a 21% pullback from the August peak. But the full tape is still brutal—down 95% from its 2020 high of $69.02, a 97% drawdown.
The growth is against an easy comparison, and management knows it. Asked to parse the U.S. beat, French offered a hedge rather than a victory lap: “the third quarter is always a bit of a mystery with regard to how much kind of headwind you are going to get from the softness that comes from vacations and so forth.” — Glendon E. French · 2026-10-27 Guidance was reiterated, not raised: $90 million to $92 million for 2026. Hitting that requires $23 million to $25 million in Q4, implying roughly flat to high-single-digit growth—not the double-digit exit the company keeps promising unless the high end is achieved. The EBITDA loss narrowed sharply, to $3.5 million from $8.2 million, a nearly 60% reduction. That is real operating leverage. The question is whether it is a cost story masquerading as a growth story.
The junior-rep experiment
The most company-specific theme in this call is the sales force. Pulmonx has substantially filled its open U.S. positions, but the bench is young. French laid out the arithmetic plainly:
That is the junior rep problem in one sentence. Prior management had a 6-to-9-month ramp assumption; on the July call, French said “the 6 to 9 months is what is correct in terms of what we've seen historically.” — Glendon French, President and Chief Executive Officer · 2026-07-29 Today the company is betting that promoting territory account managers—TAMs—into quota-carrying roles shortens that curve. One data point is genuinely encouraging: the region that is number one in dollar growth over prior year is composed entirely of people who started as TAMs or junior reps and were promoted. The average tenure is short, but the promotion pipeline is producing.About a year and a half ago, the mean and median tenure of our US sales organization was about 3 years. And today, the mean is about 1.8 years, and the median is about 1.2 years.
The far strategy—near-to-far account development—remains the operating doctrine: same-store sales first, new accounts opportunistically. Digital advertising is producing a lower cost per patient engagement and better conversion to treatment, and the company is pushing dedicated valve program coordinators into accounts. None of this is new; it is the same strategy from the April and July calls. What is new is that the revenue line finally bent upward. The risk is that a 6% growth rate is not enough to distinguish a genuine inflection from a seasonal bounce off a depressed base.
China gets reframed; AeriSeal stays distant
For several quarters, China was a recurring focal point—registration renewal, shipment timing, distributor restocking. This quarter, management actively tried to shrink its importance. French noted that when China comes back online, “it will represent about 2% of our business,” — Glendon E. French · 2026-10-27 adding that it is a distributor market and therefore lumpy. The phrase cheering for China captures the new tone: supportive but no longer central. The registration certificate is renewed and shipments should resume by early next year, but investors are being told not to model a bolus. That is a notable de-emphasis of a theme that once carried more narrative weight.
AeriSeal remains the longer-term TAM expander—roughly 20% global market expansion—but the timeline has not accelerated. Enrollment in the CONVERT II trial is on track to complete in the back half of next year; commercial launch in Europe with AeriSeal is expected in 2027 in limited fashion, with material revenue in 2028. That is a 2028 story for a company that needs a 2027 bridge.
The cash clock
The cost cuts are the strongest part of the print. Operating expenses fell 18% to $24.9 million, and management guided full-year opex to $108 million to $109 million. Gross margin was 76%, and the company expects about 77% for the year—a remarkably stable margin line for a company that has struggled to grow. The CFO was explicit that the cost base is now a keeper: “we are quite comfortable right now with where our cost structure sits.” — Derrick Sung · 2026-10-27
But the balance sheet is the tension. Pulmonx ended the quarter with $52.7 million in cash and expects to burn roughly $22 million this year. Effective net cash was negative $6 million in the last filed quarter, and the company carries debt extended to 2031 plus $20 million of undrawn capacity tied to revenue milestones. The math is workable: about $72.7 million of liquidity against a $22 million burn gives roughly three years. But the phrase cash flow breakeven has been used before. On the July call, the CFO said “we feel like we can clearly get the cash flow break even over the next few years.” — Derrick Sung, Chief Operating Officer and Chief Financial Officer · 2026-07-29 Today he repeated the clear pathway language. Investors have heard it. The difference is that the EBITDA loss is now small enough that the claim is more credible—if growth holds.
At 0.6x revenue and an $85 million market cap, the stock is pricing permanent stagnation. The tape has already voted for a change in trajectory; the fundamentals have not yet confirmed it. The quarter is a credible first step, not a victory lap. The next two quarters need to show the junior reps ramping, the cost base holding, and the cash balance not becoming the story. There is no sector-wide wave here—the global keyword tape is dominated by AI data centers, tariffs, and Fed policy. Pulmonx is an idiosyncratic micro-cap trying to prove that its own rebuild is real.